|
GB1293565A
(en)
|
1969-05-03 |
1972-10-18 |
Aspro Nicholas Ltd |
Aminophthalazines and pharmaceutical compositions thereof
|
|
GB1303061A
(enrdf_load_stackoverflow)
*
|
1969-05-03 |
1973-01-17 |
|
|
|
GB2063249A
(en)
*
|
1979-10-09 |
1981-06-03 |
Mitsubishi Yuka Pharma |
4-Phenylphthalazine derivatives
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
WO1989011279A1
(en)
|
1988-05-16 |
1989-11-30 |
Georgia State University Foundation, Inc. |
Nucleic acid interacting unfused heteropolycyclic compounds
|
|
ES2068413T3
(es)
|
1990-03-30 |
1995-04-16 |
Mitsubishi Chem Ind |
Derivados de 4-fenilftalazina.
|
|
JPH03284669A
(ja)
*
|
1990-03-30 |
1991-12-16 |
Mitsubishi Kasei Corp |
４―フェニルフタラジン誘導体
|
|
TW279162B
(enrdf_load_stackoverflow)
*
|
1991-09-26 |
1996-06-21 |
Mitsubishi Chem Corp |
|
|
DE69228069T2
(de)
|
1992-01-23 |
1999-05-20 |
Pfizer Inc., New York, N.Y. |
4-Phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxochinolin Derivate, als antihypercholesterolemische und antiatherosklerotische Mittel
|
|
US5565472A
(en)
|
1992-12-21 |
1996-10-15 |
Pfizer Inc. |
4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
|
|
DE4417746A1
(de)
|
1994-05-20 |
1995-11-23 |
Bayer Ag |
Neue Farbstoffe zum Massefärben von Kunststoffen
|
|
AU705229B2
(en)
*
|
1994-08-09 |
1999-05-20 |
Eisai R&D Management Co., Ltd. |
Fused pyridazine compound
|
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
|
KR100485249B1
(ko)
*
|
1996-08-20 |
2005-09-09 |
에자이 가부시키가이샤 |
축합피리다진계화합물의발기기능부전증치료제
|
|
US20030124053A1
(en)
|
1996-10-07 |
2003-07-03 |
Barrett John Andrew |
Radiopharmaceuticals for imaging infection and inflammation
|
|
US6235752B1
(en)
|
1996-12-18 |
2001-05-22 |
Neurogen Corporation |
Isoquinolinamine and phthalazinamine derivatives which interact with CRF receptors
|
|
US6486158B1
(en)
|
1998-08-14 |
2002-11-26 |
Cell Pathways, Inc. |
[4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
|
|
AU765128B2
(en)
|
1999-03-22 |
2003-09-11 |
Bristol-Myers Squibb Company |
Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
|
|
JP2005510568A
(ja)
|
2001-11-30 |
2005-04-21 |
ファイザー・プロダクツ・インク |
アリール基が結合したアザポリサイクリック化合物
|
|
WO2004099158A1
(en)
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Monocyclic diazodioxide based bcl-2 protein antagonists
|
|
WO2005016000A1
(en)
|
2003-08-05 |
2005-02-24 |
Avalon Pharmaceuticals |
Derivatives of cyclic quinone and uses thereof
|
|
US7087621B2
(en)
|
2003-09-05 |
2006-08-08 |
Bristol-Myers Squibb Company |
Benzo- and azabenzodithiazole compounds
|
|
US8067608B2
(en)
|
2003-09-29 |
2011-11-29 |
The Johns Hopkins University |
Hedgehog pathway antagonists
|
|
WO2006004589A2
(en)
*
|
2004-05-08 |
2006-01-12 |
Neurogen Corporation |
3-aryl-5,6-disubstituted pyridazines
|
|
CA2569849C
(en)
|
2004-06-09 |
2012-11-27 |
Erick M. Carreira |
Monophosphine compounds, transition metal complexes thereof and production of optically active compounds using the complexes as asymmetric catalysts
|
|
US20060156485A1
(en)
|
2005-01-14 |
2006-07-20 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
|
WO2006090273A2
(en)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
|
|
WO2006110516A1
(en)
|
2005-04-11 |
2006-10-19 |
Abbott Laboratories |
Acylhydrazide p2x7 antagonists and uses thereof
|
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
|
BRPI0617534A2
(pt)
|
2005-09-23 |
2011-07-26 |
Memory Pharm Corp |
Composto, composição farmacêutica, método para a ativação/estimulação seletiva de receptores nicotínicos de a-7 em um paciente, método para o tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de degeneração da memória e/ou da cognição, método para o tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método para o tratamento de um paciente que sofre de degeneração da memória devida à degeneração cognitiva suave devida ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do cns, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método para o tratamento e/ou a prevenção da demência em um paciente com mal de alzheimer, método para o tratamento de um paciente para a retirada do álcool ou para o tratamento de um paciente com terapia anti-intoxicação, método para o tratamento de um paciente para conferir neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamato, método para o tratamento de um paciente que sofre de vício de nicotina, dor, tontura de fuso horário, obesidade e/ou diabetes, método de indução de um paciente a parar de fumar, método para o tratamento de um paciente que sofre de degeneração cognitiva suave (mci), demência vascular (vad), declínio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia de coração aberto, apreensão cardíaca, anestesia geral, déficits da memória devido à exposição a agentes anestésicos(...)
|
|
FR2891828B1
(fr)
|
2005-10-12 |
2007-12-21 |
Sanofi Aventis Sa |
Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
|
|
JP2009514883A
(ja)
|
2005-11-03 |
2009-04-09 |
イリプサ， インコーポレイテッド |
アザインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
|
|
EP1960356A2
(en)
|
2005-11-03 |
2008-08-27 |
Ilypsa, Inc. |
Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
|
|
US20070179123A1
(en)
|
2005-11-08 |
2007-08-02 |
Chiang Peter K |
Methods and compositions for treating diseases associated with pathogenic proteins
|
|
JP2009120486A
(ja)
*
|
2005-12-05 |
2009-06-04 |
Mitsubishi Pharma Corp |
核内オーファン受容体の新規活性化剤及びその用途
|
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
|
ES2502790T3
(es)
|
2006-01-23 |
2014-10-06 |
Amgen Inc. |
Moduladores de la cinasa Aurora y método de uso
|
|
CN101426779B
(zh)
|
2006-02-16 |
2013-08-21 |
先正达参股股份有限公司 |
含有二环双酰胺结构的农药
|
|
US20090318476A1
(en)
|
2006-08-09 |
2009-12-24 |
Merck Frosst Canada Ltd. |
Azacycloalkane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
|
|
MX2009011208A
(es)
|
2007-04-19 |
2009-10-30 |
Novartis Ag |
Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
|
|
EP2155746A2
(en)
|
2007-05-04 |
2010-02-24 |
Amgen, Inc |
Diazaquinolones that inhibit prolyl hydroxylase activity
|
|
US9023490B2
(en)
|
2007-06-15 |
2015-05-05 |
Versitech Limited |
Extended pi-conjugated platinum (II) complexes
|
|
AU2008300019A1
(en)
|
2007-09-07 |
2009-03-19 |
Amgen Inc. |
Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
|
|
US20090082358A1
(en)
|
2007-09-20 |
2009-03-26 |
Nobuko Nishimura |
Vanilloid receptor ligands and their use in treatments
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
EP2234618A4
(en)
|
2007-12-21 |
2011-04-27 |
Scripps Research Inst |
BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
|
|
US8932557B2
(en)
|
2008-02-14 |
2015-01-13 |
Eli Lilly And Company |
Imaging agents for detecting neurological dysfunction
|
|
AU2009234280A1
(en)
|
2008-04-11 |
2009-10-15 |
The Regents Of The University Of Michigan |
Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
|
|
WO2009140163A1
(en)
|
2008-05-15 |
2009-11-19 |
Merck & Co., Inc. |
Oxazolobenzimidazole derivatives
|
|
AU2009259754B2
(en)
|
2008-06-16 |
2014-10-02 |
Merck Patent Gmbh |
Quinoxalinedione derivatives
|
|
WO2009157386A1
(ja)
|
2008-06-25 |
2009-12-30 |
住友化学株式会社 |
光学活性アミン化合物の製造方法
|
|
EP2318401A4
(en)
|
2008-08-16 |
2013-10-30 |
Genentech Inc |
AZAINDOLI INHIBITORS OF IPA
|
|
AU2009296931A1
(en)
|
2008-09-26 |
2010-04-01 |
Merck Sharp & Dohme Corp. |
Oxazolobenzimidazole derivatives
|
|
EA201171098A1
(ru)
|
2009-03-02 |
2012-04-30 |
Сертрис Фармасьютикалз, Инк. |
8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
|
|
TW201040191A
(en)
|
2009-03-27 |
2010-11-16 |
Abbott Gmbh & Co Kg |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
EP2414353A1
(en)
|
2009-04-01 |
2012-02-08 |
Basf Se |
Isoxazoline compounds for combating invertebrate pests
|
|
US9593108B2
(en)
|
2009-04-06 |
2017-03-14 |
Ptc Therapeutics, Inc. |
Compounds and methods for antiviral treatment
|
|
EP2416772A1
(en)
|
2009-04-06 |
2012-02-15 |
PTC Therapeutics, Inc. |
Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
|
|
CA2765823A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Tricyclic heterocyclic compounds as mediators of p13k activity
|
|
US8981087B2
(en)
|
2009-07-29 |
2015-03-17 |
Karus Therapeutics Limited |
Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
|
|
EP2464647B1
(en)
|
2009-08-11 |
2016-09-21 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
|
WO2011075607A1
(en)
|
2009-12-18 |
2011-06-23 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
|
UY33304A
(es)
|
2010-04-02 |
2011-10-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
JP5826261B2
(ja)
|
2010-06-28 |
2015-12-02 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
|
|
CA2803620A1
(en)
|
2010-06-30 |
2012-01-05 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
CA2812088A1
(en)
|
2010-09-14 |
2012-03-22 |
Exelixis, Inc. |
Phtalazine derivatives as jak1 inhibitors
|
|
WO2012041814A1
(en)
|
2010-09-27 |
2012-04-05 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
MX2013013211A
(es)
|
2011-05-18 |
2014-02-20 |
Syngenta Participations Ag |
Compuestos insecticidas a base de derivados de ariltioacetamida.
|
|
CA2844469C
(en)
|
2011-08-08 |
2019-08-20 |
Merck Patent Gmbh |
N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
|
|
WO2013026939A1
(en)
|
2011-08-25 |
2013-02-28 |
Syngenta Participations Ag |
Methods for the control of termites and ants
|
|
WO2013078254A1
(en)
|
2011-11-22 |
2013-05-30 |
Array Biopharma Inc. |
Bicyclic heteroaryl derivatives as kinase inhibitors
|
|
UA112897C2
(uk)
|
2012-05-09 |
2016-11-10 |
Байєр Фарма Акцієнгезелльшафт |
Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
|
|
CA2873963C
(en)
|
2012-05-22 |
2017-04-11 |
Eli Lilly And Company |
Carboline and carbazole based imaging agents for detecting neurological dysfunction
|
|
TWI610916B
(zh)
|
2012-08-03 |
2018-01-11 |
廣東東陽光藥業有限公司 |
作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
|
|
WO2014079935A1
(en)
|
2012-11-21 |
2014-05-30 |
Syngenta Participations Ag |
Insecticidal compounds based on arylthioacetamide derivatives
|
|
EP2922837A1
(en)
|
2012-11-21 |
2015-09-30 |
Syngenta Participations AG |
Insecticidal compounds based on n-(arylsulfanylmethyl) carboxamide derivatives
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
WO2014086737A1
(de)
|
2012-12-06 |
2014-06-12 |
Bayer Cropscience Ag |
Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide
|
|
TW201439060A
(zh)
|
2013-02-27 |
2014-10-16 |
Sunshine Lake Pharma Co Ltd |
作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
|
|
GB201311953D0
(en)
*
|
2013-07-03 |
2013-08-14 |
Redx Pharma Ltd |
Compounds
|
|
AR097631A1
(es)
|
2013-09-16 |
2016-04-06 |
Bayer Pharma AG |
Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
|
|
UY35809A
(es)
|
2013-11-05 |
2015-05-29 |
Bayer Pharma AG |
(aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
|
|
EA032559B1
(ru)
|
2014-04-04 |
2019-06-28 |
Пфайзер Инк. |
Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
|
|
CN103992311B
(zh)
*
|
2014-06-20 |
2017-01-25 |
东南大学 |
Hedgehog信号通路抑制剂
|
|
US9617279B1
(en)
|
2014-06-24 |
2017-04-11 |
Bristol-Myers Squibb Company |
Imidazooxadiazole compounds
|
|
EP3224258B1
(en)
|
2014-11-27 |
2019-08-14 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
RU2021100040A
(ru)
|
2014-12-22 |
2021-02-02 |
Акарна Терапьютикс, Лтд. |
Конденсированные бициклические соединения для лечения заболевания
|
|
WO2016123796A1
(en)
|
2015-02-06 |
2016-08-11 |
Abbvie Inc. |
Substituted phthalazines
|
|
CA2975192A1
(en)
|
2015-02-16 |
2016-08-25 |
The University Of Queensland |
Sulfonylureas and related compounds and use of same
|
|
AU2016366694C1
(en)
|
2015-12-10 |
2021-03-25 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
|
FR3046933B1
(fr)
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
SG11201806700RA
(en)
|
2016-02-12 |
2018-09-27 |
Pharmaxis Ltd |
Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
|
|
MX2018009840A
(es)
|
2016-02-16 |
2019-01-21 |
Univ Queensland |
Sulfonilureas y compuestos relacionados y sus usos.
|
|
WO2017144341A1
(de)
|
2016-02-23 |
2017-08-31 |
Bayer Cropscience Aktiengesellschaft |
Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
|
|
WO2017184604A1
(en)
|
2016-04-18 |
2017-10-26 |
Ifm Therapeutics, Inc |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3236267B1
(en)
|
2016-04-18 |
2021-09-08 |
Roche Diagnostics GmbH |
Decapper and apparatus
|
|
AU2017254523B2
(en)
|
2016-04-18 |
2021-09-02 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
EP3272739A1
(en)
|
2016-07-20 |
2018-01-24 |
NodThera Limited |
Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
|
|
WO2018031680A1
(en)
|
2016-08-10 |
2018-02-15 |
Fronthera U.S. Pharmaceuticals Llc |
Novel compounds, uses and methods for their preparation
|
|
US10947241B2
(en)
*
|
2016-10-28 |
2021-03-16 |
Seoul National University Hospital |
Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
|
|
WO2018138050A1
(de)
|
2017-01-26 |
2018-08-02 |
Bayer Aktiengesellschaft |
Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
|
|
EP3577109A4
(en)
|
2017-01-31 |
2020-11-18 |
Arvinas Operations, Inc. |
CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
|
|
WO2018172925A1
(en)
|
2017-03-23 |
2018-09-27 |
Vitas Pharma Research Pvt Ltd |
Inhibitors of dna gyrase for treatment of bacterial infections
|
|
KR101943428B1
(ko)
|
2017-03-24 |
2019-01-30 |
엘티소재주식회사 |
유기 발광 소자 및 유기 발광 소자의 유기물층용 조성물
|
|
WO2018174678A1
(ko)
|
2017-03-24 |
2018-09-27 |
희성소재(주) |
헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
WO2018221433A1
(ja)
|
2017-05-29 |
2018-12-06 |
第一三共株式会社 |
ヘテロアリールアミン誘導体
|
|
JP6849248B2
(ja)
|
2017-07-20 |
2021-03-24 |
エルジー・ケム・リミテッド |
化合物およびこれを含む有機発光素子
|
|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
JP7287952B2
(ja)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
|
|
CN110526898A
(zh)
|
2018-05-25 |
2019-12-03 |
北京诺诚健华医药科技有限公司 |
3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
|
|
CN110563722A
(zh)
*
|
2018-06-06 |
2019-12-13 |
上海青煜医药科技有限公司 |
吡啶或哒嗪并环化合物及其应用
|
|
WO2020021015A1
(en)
|
2018-07-26 |
2020-01-30 |
Esteve Pharmaceuticals, S.A. |
New imidazopyridine derivatives for treating pain and pain related conditions
|
|
US20200075870A1
(en)
|
2018-08-22 |
2020-03-05 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
|
WO2020163248A1
(en)
|
2019-02-04 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
KR102721075B1
(ko)
|
2019-02-15 |
2024-10-24 |
삼성전자주식회사 |
축합환 화합물 및 이를 포함한 유기 발광 소자
|
|
AR119731A1
(es)
*
|
2019-05-17 |
2022-01-05 |
Novartis Ag |
Inhibidores del inflamasoma nlrp3
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
JPWO2021193897A1
(enrdf_load_stackoverflow)
*
|
2020-03-27 |
2021-09-30 |
|
|
|
EP4157823A1
(en)
|
2020-05-28 |
2023-04-05 |
JANSSEN Pharmaceutica NV |
Compounds
|
|
AU2021286560A1
(en)
|
2020-06-09 |
2023-02-02 |
Pardes Biosciences, Inc. |
Inhibitors of cysteine proteases and methods of use thereof
|
|
CN116390914A
(zh)
|
2020-12-25 |
2023-07-04 |
上海拓界生物医药科技有限公司 |
一类含哒嗪的化合物及其医药用途
|
|
US20240166610A1
(en)
|
2021-02-08 |
2024-05-23 |
Medshine Discovery Inc. |
Substituted pyridazine phenol derivatives
|
|
CA3214040A1
(en)
|
2021-04-07 |
2022-10-13 |
Forma Therapeutics, Inc. |
Inhibiting ubiquitin-specific protease 1 (usp1)
|
|
US11319319B1
(en)
*
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
MX2023012795A
(es)
|
2021-04-28 |
2023-11-08 |
Astellas Pharma Inc |
Compuesto de triazina sustituida.
|
|
BR112023022471A2
(pt)
|
2021-04-29 |
2024-01-16 |
Janssen Pharmaceutica Nv |
Derivados de ftalazinona como inibidores de inflamassoma nlrp3
|
|
CA3214626A1
(en)
|
2021-05-12 |
2022-11-17 |
F. Hoffmann-La Roche Ag |
Nlrp3 inhibitors
|
|
CA3216026A1
(en)
|
2021-06-04 |
2022-12-08 |
F. Hoffmann-La Roche Ag |
Triazine derivatives and their use in the treatment of cancer
|
|
US20240294542A1
(en)
|
2021-06-05 |
2024-09-05 |
Transthera Sciences (Nanjing), Inc. |
Nlrp3 inflammasome inhibitor and application thereof
|
|
WO2023278438A1
(en)
|
2021-06-29 |
2023-01-05 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
JP2024523623A
(ja)
|
2021-07-02 |
2024-06-28 |
アストラゼネカ・アクチエボラーグ |
Ｎｌｒｐ３インフラマソーム阻害剤
|
|
WO2023283256A1
(en)
|
2021-07-09 |
2023-01-12 |
Aligos Therapeutics, Inc. |
Anti-viral compounds
|
|
CA3226995A1
(en)
|
2021-07-21 |
2023-01-26 |
Nico Therapeutics, Inc. |
Annulated pyridazine compound
|
|
PE20241727A1
(es)
|
2021-08-25 |
2024-08-19 |
Ptc Therapeutics Inc |
Inhibidores de nlrp3
|
|
WO2023028536A1
(en)
|
2021-08-25 |
2023-03-02 |
Ptc Therapeutics, Inc. |
1,2,4-triazine derivatives useful as inhibitors of nlrp3
|
|
CA3226855A1
(en)
|
2021-08-25 |
2023-03-02 |
Zydus Lifesciences Limited |
Treatment for neuroinflammatory disorders
|
|
CA3233482A1
(en)
|
2021-09-30 |
2023-04-06 |
Origiant Pharmaceutical Co., Ltd |
Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
|
|
WO2023066825A1
(en)
|
2021-10-19 |
2023-04-27 |
F. Hoffmann-La Roche Ag |
Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors
|
|
CN116102535A
(zh)
|
2021-10-22 |
2023-05-12 |
索智生物科技（浙江）有限公司 |
一种含氮化合物、其制备方法及应用
|
|
WO2023088856A1
(en)
|
2021-11-17 |
2023-05-25 |
F. Hoffmann-La Roche Ag |
Heterocyclic nlrp3 inhibitors
|
|
AR127704A1
(es)
|
2021-11-19 |
2024-02-21 |
Hoffmann La Roche |
Derivados de piridazina inhibidores de nlrp3
|
|
WO2023129987A1
(en)
|
2021-12-29 |
2023-07-06 |
Neumora Therapeutics, Inc. |
Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
|
|
JP2025501373A
(ja)
|
2022-01-07 |
2025-01-17 |
薬捷安康（南京）科技股▲分▼有限公司 |
Ｎｌｒｐ３インフラマソーム阻害剤およびその使用
|
|
CN116726020A
(zh)
|
2022-03-08 |
2023-09-12 |
上海拓界生物医药科技有限公司 |
一类含哒嗪的化合物的药物组合物及其医药用途
|
|
IL315592A
(en)
|
2022-03-15 |
2024-11-01 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
KR20250005125A
(ko)
|
2022-03-25 |
2025-01-09 |
벤투스 테라퓨틱스 유에스 인코포레이티드 |
NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
|
|
JP2025511199A
(ja)
|
2022-03-31 |
2025-04-15 |
ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド |
Ｎｌｒｐ３インフラマソーム阻害剤
|
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
|
CN116969920A
(zh)
|
2022-04-29 |
2023-10-31 |
上海辉启生物医药科技有限公司 |
稠合哒嗪衍生物及其制备方法与医药用途
|
|
US20230365534A1
(en)
|
2022-05-13 |
2023-11-16 |
Neumora Therapeutics, Inc. |
Modulators of nlrp3 inflammasome and related products and methods
|
|
WO2023232917A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Novel compounds
|
|
WO2024006559A1
(en)
|
2022-07-01 |
2024-01-04 |
Neumora Therapeutics, Inc. |
Modulators of nlrp3 inflammasome and related products and methods
|
|
AU2023307538A1
(en)
|
2022-07-14 |
2025-01-23 |
Ac Immune Sa |
Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
|
|
CN119546599A
(zh)
|
2022-07-14 |
2025-02-28 |
南京明德新药研发有限公司 |
氘取代的哒嗪苯并噻吩化合物及其应用
|
|
EP4558499A1
(en)
|
2022-07-21 |
2025-05-28 |
F. Hoffmann-La Roche AG |
Nlrp3 inhibitors
|
|
US20240101563A1
(en)
|
2022-07-28 |
2024-03-28 |
Ac Immune Sa |
Novel compounds
|
|
AR130094A1
(es)
|
2022-08-03 |
2024-10-30 |
Novartis Ag |
Inhibidores de inflamasoma nlrp3
|
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN116789674B
(zh)
|
2022-08-24 |
2024-05-24 |
杭州高光制药有限公司 |
Nlrp3炎性小体抑制剂
|
|
AR130548A1
(es)
|
2022-09-23 |
2024-12-18 |
Merck Sharp & Dohme Llc |
Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod
|
|
TW202432551A
(zh)
|
2022-10-26 |
2024-08-16 |
日商安斯泰來製藥股份有限公司 |
稠環嗒嗪衍生物
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
WO2024097629A1
(en)
|
2022-10-31 |
2024-05-10 |
Ventus Therapeutics U.S., Inc. |
Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
|
|
WO2024097598A1
(en)
|
2022-11-02 |
2024-05-10 |
Merck Sharp & Dohme Llc |
Triazines useful as inhibitors of nod-like receptor protein 3
|
|
WO2024094150A1
(en)
|
2022-11-04 |
2024-05-10 |
Insilico Medicine Ip Limited |
Nlrp3 inflammasome inhibitors and uses thereof
|
|
TW202419090A
(zh)
|
2022-11-04 |
2024-05-16 |
大陸商藥捷安康(南京)科技股份有限公司 |
Nlrp3炎症小體抑制劑及其應用
|
|
WO2024099993A1
(en)
|
2022-11-09 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Triazinone derivatives as nlrp3 inhibitors
|
|
PE20251675A1
(es)
|
2022-11-09 |
2025-06-30 |
F Hoffmann La Roche Ag |
Derivados de triazinona como inhibidores de nlrp3
|
|
AU2023376398A1
(en)
|
2022-11-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Triazinone derivatives as nlrp3 inhibitors
|
|
CN118056822A
(zh)
|
2022-11-18 |
2024-05-21 |
正大天晴药业集团股份有限公司 |
一种哒嗪并环化合物及其用途
|
|
WO2024109922A1
(zh)
|
2022-11-25 |
2024-05-30 |
成都赜灵生物医药科技有限公司 |
桥环并哒嗪类化合物及其用途
|
|
KR20250116028A
(ko)
|
2022-12-07 |
2025-07-31 |
에프. 호프만-라 로슈 아게 |
Nlrp3 억제 조절제로서의 신규 화합물
|
|
WO2024121184A1
(en)
|
2022-12-08 |
2024-06-13 |
F. Hoffmann-La Roche Ag |
Inhibitors of nlrp3
|
|
WO2024137319A1
(en)
|
2022-12-19 |
2024-06-27 |
Merck Sharp & Dohme Llc |
6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
CN120513236A
(zh)
|
2022-12-23 |
2025-08-19 |
纽摩拉治疗公司 |
Nlrp3炎症小体的调节剂和相关产品以及方法
|
|
WO2024140704A1
(zh)
|
2022-12-27 |
2024-07-04 |
正大天晴药业集团股份有限公司 |
一种哒嗪稠芳环化合物及其用途
|
|
KR20250106322A
(ko)
|
2022-12-28 |
2025-07-09 |
장춘 진사이언스 파마슈티컬 씨오., 엘티디. |
피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
|
|
WO2024141535A1
(en)
|
2022-12-28 |
2024-07-04 |
Astrazeneca Ab |
Nlrp3 inflammasome inhibitors
|
|
AU2023414924A1
(en)
|
2022-12-30 |
2025-07-03 |
Ptc Therapeutics, Inc. |
Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
|
|
AU2024206808A1
(en)
|
2023-01-03 |
2025-07-17 |
Kodiak Sciences Inc. |
Organic compounds as nlrp3 inhibitors
|
|
WO2024160693A1
(en)
|
2023-01-31 |
2024-08-08 |
Janssen Pharmaceutica Nv |
Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
|
|
WO2024160691A1
(en)
|
2023-01-31 |
2024-08-08 |
Janssen Pharmaceutica Nv |
PYRROLO[1,2-d][1,2,4]TRIAZINES AND PYRAZOLO[1,5-d] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS
|
|
WO2024160690A1
(en)
|
2023-01-31 |
2024-08-08 |
Janssen Pharmaceutica Nv |
2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors
|
|
WO2024160694A1
(en)
|
2023-01-31 |
2024-08-08 |
Janssen Pharmaceutica Nv |
[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
|
|
WO2024160692A1
(en)
|
2023-01-31 |
2024-08-08 |
Janssen Pharmaceutica Nv |
Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
|